Synthego spent nearly a decade building CRISPR-based tools to help researchers in academia and biotech run experiments. The company is shifting into manufacturing and aims to become the "manufacturing bedrock for CRISPR." The article reports Synthego has secured $200M in new cash to support that move. Paul Dabrowski is identified as Synthego's CEO. No revenue, user metrics, or detailed financial terms are provided in the article. The piece frames the funding as enabling a new strategic focus on manufacturing rather than additional product R&D alone. Synthego, based in Redwood City, Calif., builds platforms that combine machine learning, automation and gene editing to enable life‑science research at scale. The company produces standardized CRISPR reagents and engineered cells to accelerate discovery, validation and genetic‑pathway analysis for basic research, target identification and clinical trials. Its platforms are designed to enable more rapid and precise work by scientists and support translational R&D. The company said it will use proceeds from the financing to expand the capabilities of its proprietary platforms. Synthego recently appointed Robert (Bob) Deans, Ph.D., as Chief Scientific Officer and John Tan, M.B.A., as Chief Operating Officer. The new financing brings the company’s total private funding to more than $250m. Synthego, led by co-founder and CEO Paul Dabrowski, develops an automated, full-stack genome engineering platform that leverages automation, bioinformatics, and machine learning. The platform is designed to enable access to CRISPR to accelerate basic scientific discovery, uncover critical disease cures, and develop novel synthetic biology applications. The company intends to use the new funds to accelerate CRISPR capabilities for rapid and precise genome engineering in applications such as cell and gene therapies. In conjunction with the funding, Dr. Matthew Porteus joined Synthego’s advisory board alongside industry leaders Sir Andrew Witty and Dr. Jennifer Doudna. The company is based in Redwood City, California and the Series C brings total funding to $160m. Synthego provides genome engineering solutions including software and synthetic RNA kits designed for CRISPR genome editing and research. The company is led by Rich Stoner, PhD, Chief Science Officer. Earlier in the year it launched CRISPR Workflow Software — a guide designer and design validator — to accelerate guide RNA design for CRISPR gene knockouts. That software spans a dataset of over 113 billion targets across more than 123,000 genomes. Customers include institutions in over 32 countries, eight of the world’s ten largest biotechnology companies, and 24 of the top 25 global biology universities. The company says it will use the investment to advance its bioinformatics tools and technologies. Synthego provides genome engineering solutions through its CRISPRevolution portfolio of synthetic RNA designed for CRISPR genome editing and research. Founded in 2012 and led by CEO Paul Dabrowski, the company positions its products to accelerate discovery in therapeutics, diagnostics, stem cell research and synthetic biology. Customers include institutions in over 30 countries and nine of the top ten global biology universities. The company raised $41M in a Series B and has raised $50M in total to date. Synthego intends to use the funds to grow commercial operations, expand internationally, and introduce new products. The company is based in Redwood City, California and aims to remove guesswork from experimental workflows.

Total raised

$451M

Funding rounds

5

Latest round

Equity

Latest activity

Feb 2022